Evidence map›Paper›PMID 39498987›Full record

ArticleJournal of virology2024

Lethal model for respiratory syncytial virus infection using C57BL/6 mice.

Tatsuki Takahashi, Sodbayasgalan Amarbayasgalan, Shiori Ueno, Yoshiro Sugiura, Enkhjin Dorjsuren, Kenta Shimizu, Wataru Kamitani

Abstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tatsuki TakahashiDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi-shi, Gunma, Japan.ORCID 0000-0002-4553-8344
Sodbayasgalan AmarbayasgalanDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi-shi, Gunma, Japan.
Shiori UenoDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi-shi, Gunma, Japan.
Yoshiro SugiuraDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi-shi, Gunma, Japan.
Enkhjin DorjsurenDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi-shi, Gunma, Japan.
Kenta ShimizuDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi-shi, Gunma, Japan.
Wataru KamitaniDepartment of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi-shi, Gunma, Japan.ORCID 0000-0003-0165-9408

Funding

KAKENHI 22K15467MEXT | JST | Moonshot Research and Development Program (Moonshot) JPMJMS2025Mother and Child Health Foundation (MCHF) R05-K1-2
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) infection is a major infectious disease affecting public health. Infants and elderly infected with RSV can develop severe respiratory symptoms. A mouse model mimicking human RSV infection could be useful in elucidating the pathogenesis of RSV. However, previous mouse models did not adequately mimic the pathophysiology of human patients. We attempted to establish a new mouse-adapted RSV strain via serial passaging of mice. We rescued the MP11 virus (which had one non-synonymous substitution in each of the F, G, and L genes) through serial passaging in mice. The MP11 virus was inoculated into mice to evaluate whether it had adapted to the mouse. Viral RNA levels in the lungs of 25-week-old mice infected with MP11 virus were higher than those in the lungs of mice infected with A2 virus. There was a high infiltration of inflammatory cells and high expression of several inflammatory cytokines (IFN-γ, CCL2, TNF-α, and IL-6) in the MP11 virus-infected lungs. Furthermore, the MP11 virus can also cause lethal pneumonia in mice via high-concentration inoculation. These results indicated that the MP11 virus is a more mouse-adapted strain than the A2 virus. We generated a recombinant MP11 virus (rMP11) using reverse genetics. The rMP11 virus could grow in the lungs of mice, similar to the parent MP11 virus. In conclusion, we successfully established a new mouse-adapted strain, MP11, and reverse genetics for this strain. These MP11 and rMP11 viruses could contribute to mouse experiments aimed at elucidating RSV pathogenesis. IMPORTANCE: A mouse model of respiratory syncytial virus (RSV) infection is useful for fundamental research aimed at developing antiviral drugs. Previous mouse models of RSV infection were unable to adequately mimic the pathophysiology of human patients due to the low amplification efficiency of this virus in the mouse lung. Furthermore, mice other than BALB/C mice are difficult to use for the RSV infectious model. We established a new mouse-adapted RSV strain, MP11. The MP11 virus can cause severe pneumonia in C57BL/6 mice and efficiently replicate and induce inflammation in the lung. Therefore, C57BL/6 mice can be used for RSV infection experiments using MP11 virus. We established a reverse genetics system for the MP11 virus using our mouse model. This system enables detailed analyses of the MP11 virus, such as functional analysis of each viral protein. Our study provides techniques that can advance fundamental research in elucidating the pathogenesis of RSV infections.

Indexed as

CytokinesDisease Models, AnimalLungMice, Inbred C57BLRespiratory Syncytial Virus InfectionsAnimalsFemaleHumansMiceRespiratory Syncytial VirusesRespiratory Syncytial Virus, HumanRNA, ViralSerial PassageVirus ReplicationCytokinesRNA, ViralC57BL/6 micecytokine responseinflammationmouse modelrespiratory syncytial virusreverse geneticsviral pathogenesisvirus infection model

Identifiers

PMID39498987
PMCPMC11651003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.